These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

279 related articles for article (PubMed ID: 33186403)

  • 1. Nineteen-year prognosis in Japanese patients with biopsy-proven nonalcoholic fatty liver disease: Lean versus overweight patients.
    Hirose S; Matsumoto K; Tatemichi M; Tsuruya K; Anzai K; Arase Y; Shiraishi K; Suzuki M; Ieda S; Kagawa T
    PLoS One; 2020; 15(11):e0241770. PubMed ID: 33186403
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characterization of lean patients with nonalcoholic fatty liver disease: potential role of high hemoglobin levels.
    Akyuz U; Yesil A; Yilmaz Y
    Scand J Gastroenterol; 2015 Mar; 50(3):341-6. PubMed ID: 25540973
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Liver and Cardiovascular Damage in Patients With Lean Nonalcoholic Fatty Liver Disease, and Association With Visceral Obesity.
    Fracanzani AL; Petta S; Lombardi R; Pisano G; Russello M; Consonni D; Di Marco V; Cammà C; Mensi L; Dongiovanni P; Valenti L; Craxì A; Fargion S
    Clin Gastroenterol Hepatol; 2017 Oct; 15(10):1604-1611.e1. PubMed ID: 28554682
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Caucasian lean subjects with non-alcoholic fatty liver disease share long-term prognosis of non-lean: time for reappraisal of BMI-driven approach?
    Younes R; Govaere O; Petta S; Miele L; Tiniakos D; Burt A; David E; Vecchio FM; Maggioni M; Cabibi D; McLeod D; Pareja MJ; Fracanzani AL; Aller R; Rosso C; Ampuero J; Gallego-Durán R; Armandi A; Caviglia GP; Zaki MYW; Liguori A; Francione P; Pennisi G; Grieco A; Birolo G; Fariselli P; Eslam M; Valenti L; George J; Romero-Gómez M; Anstee QM; Bugianesi E
    Gut; 2022 Feb; 71(2):382-390. PubMed ID: 33541866
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The impact of body mass index on clinicopathological features of nonalcoholic fatty liver disease in Taiwan.
    Lin CL; Tai CM; Huang JF; Liu CJ; Chen HF; Cheng PN; Chen CY; Peng CY; Wang CC; Weng SH; Tseng TC; Kao JH
    J Gastroenterol Hepatol; 2022 Oct; 37(10):1901-1910. PubMed ID: 35790343
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fibrosis stage but not NASH predicts mortality and time to development of severe liver disease in biopsy-proven NAFLD.
    Hagström H; Nasr P; Ekstedt M; Hammar U; Stål P; Hultcrantz R; Kechagias S
    J Hepatol; 2017 Dec; 67(6):1265-1273. PubMed ID: 28803953
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Growing burden of nonalcoholic fatty liver disease in Turkey: A single-center experience.
    Yılmaz Y; Kanı HT; Demirtaş CÖ; Kaya E; Sapmaz AF; Qutranji L; Alkayyali T; Batun KD; Batman M; Toy B; Çiftaslan A
    Turk J Gastroenterol; 2019 Oct; 30(10):892-898. PubMed ID: 31258138
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oxidized low-density lipoprotein antibodies/high-density lipoprotein cholesterol ratio is linked to advanced non-alcoholic fatty liver disease lean patients.
    Ampuero J; Ranchal I; Gallego-Durán R; Pareja MJ; Del Campo JA; Pastor-Ramírez H; Rico MC; Picón R; Pastor L; García-Monzón C; Andrade R; Romero-Gómez M
    J Gastroenterol Hepatol; 2016 Sep; 31(9):1611-8. PubMed ID: 26946071
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Non-invasive predictors of prognosis of Asian patients with histopathologically-confirmed lean nonalcoholic fatty liver disease.
    Iritani S; Akuta N; Kawamura Y; Kajiwara A; Kasuya K; Fujiyama S; Sezaki H; Hosaka T; Kobayashi M; Kobayashi M; Saito S; Suzuki F; Arase Y; Ikeda K; Suzuki Y; Kumada H
    BMC Gastroenterol; 2020 Nov; 20(1):368. PubMed ID: 33148171
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Liver Fibrosis, but No Other Histologic Features, Is Associated With Long-term Outcomes of Patients With Nonalcoholic Fatty Liver Disease.
    Angulo P; Kleiner DE; Dam-Larsen S; Adams LA; Bjornsson ES; Charatcharoenwitthaya P; Mills PR; Keach JC; Lafferty HD; Stahler A; Haflidadottir S; Bendtsen F
    Gastroenterology; 2015 Aug; 149(2):389-97.e10. PubMed ID: 25935633
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Histopathological differences utilizing the nonalcoholic fatty liver disease activity score criteria in diabetic (type 2 diabetes mellitus) and non-diabetic patients with nonalcoholic fatty liver disease.
    Puchakayala BK; Verma S; Kanwar P; Hart J; Sanivarapu RR; Mohanty SR
    World J Hepatol; 2015 Nov; 7(25):2610-8. PubMed ID: 26557954
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Histopathological differences in patients with biopsy-proven non-alcoholic fatty liver disease with and without type 2 diabetes.
    Aller de la Fuente R; Mora Cuadrado N; Tafur C; López Gómez JJ; Gómez de la Cuesta S; García Sánchez MC; Antolin Melero B; de Luis Román DA
    Endocrinol Diabetes Nutr (Engl Ed); 2018; 65(6):354-360. PubMed ID: 29477355
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Significant fibrosis predicts new-onset diabetes mellitus and arterial hypertension in patients with NASH.
    Ampuero J; Aller R; Gallego-Durán R; Crespo J; Calleja JL; García-Monzón C; Gómez-Camarero J; Caballería J; Lo Iacono O; Ibañez L; García-Samaniego J; Albillos A; Francés R; Fernández-Rodríguez C; Diago M; Soriano G; Andrade RJ; Latorre R; Jorquera F; Morillas RM; Escudero D; Estévez P; Guerra MH; Augustín S; Banales JM; Aspichueta P; Benlloch S; Rosales JM; Salmerón J; Turnes J; Romero Gómez M;
    J Hepatol; 2020 Jul; 73(1):17-25. PubMed ID: 32147361
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic Value of Non-Invasive Fibrosis and Steatosis Tools, Hepatic Venous Pressure Gradient (HVPG) and Histology in Nonalcoholic Steatohepatitis.
    Sebastiani G; Alshaalan R; Wong P; Rubino M; Salman A; Metrakos P; Deschenes M; Ghali P
    PLoS One; 2015; 10(6):e0128774. PubMed ID: 26083565
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mortality in biopsy-confirmed nonalcoholic fatty liver disease: results from a nationwide cohort.
    Simon TG; Roelstraete B; Khalili H; Hagström H; Ludvigsson JF
    Gut; 2021 Jul; 70(7):1375-1382. PubMed ID: 33037056
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association Between Fibrosis Stage and Outcomes of Patients With Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis.
    Taylor RS; Taylor RJ; Bayliss S; Hagström H; Nasr P; Schattenberg JM; Ishigami M; Toyoda H; Wai-Sun Wong V; Peleg N; Shlomai A; Sebastiani G; Seko Y; Bhala N; Younossi ZM; Anstee QM; McPherson S; Newsome PN
    Gastroenterology; 2020 May; 158(6):1611-1625.e12. PubMed ID: 32027911
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characterization of biopsy proven non-alcoholic fatty liver disease in healthy non-obese and lean population of living liver donors: The impact of uric acid.
    Eshraghian A; Nikeghbalian S; Geramizadeh B; Kazemi K; Shamsaeefar A; Malek-Hosseini SA
    Clin Res Hepatol Gastroenterol; 2020 Sep; 44(4):572-578. PubMed ID: 31611031
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predictors of all-cause mortality and liver-related mortality in patients with non-alcoholic fatty liver disease (NAFLD).
    Stepanova M; Rafiq N; Makhlouf H; Agrawal R; Kaur I; Younoszai Z; McCullough A; Goodman Z; Younossi ZM
    Dig Dis Sci; 2013 Oct; 58(10):3017-23. PubMed ID: 23775317
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lean nonalcoholic fatty liver disease and risk of incident type 2 diabetes mellitus: A literature review and meta-analysis.
    Gao Y; Zhao T; Song S; Duo Y; Gao J; Yuan T; Zhao W
    Diabetes Res Clin Pract; 2023 Jun; 200():110699. PubMed ID: 37169306
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Irisin in patients with nonalcoholic fatty liver disease.
    Polyzos SA; Kountouras J; Anastasilakis AD; Geladari EV; Mantzoros CS
    Metabolism; 2014 Feb; 63(2):207-17. PubMed ID: 24140091
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.